Skip to main content

Advertisement

SpringerLink
Log in

Cardiovascular diseases

Lipid-lowering in CKD—at the SHARP end of the evidence?

  • News & Views
  • Published:

From Nature Reviews Nephrology

View current issue Sign up to alerts

Patients with chronic kidney disease (CKD) are at increased risk of cardiovascular disease. Following publication of the results from the SHARP trial, are we any closer to knowing whether statins are beneficial for preventing cardiovascular events in patients with CKD, particularly those on dialysis?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Baigent, C. et al. for the Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267–1278 (2005).

    Article  CAS  Google Scholar 

  2. Baigent, C. et al. on behalf of the SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377, 2181–2192 (2011).

    Article  CAS  Google Scholar 

  3. Chonchol, M., Cook, T., Kjekshus, J., Pedersen, T. R. & Lindenfeld, J. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. Am.J. Kidney Dis. 49, 373–382 (2007).

    Article  CAS  Google Scholar 

  4. Kendrick, J. et al. Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. Am. J. Kidney Dis. 55, 42–49 (2010).

    Article  CAS  Google Scholar 

  5. Ridker, P. M., MacFadyen, J., Cressman, M. & Glynn, R. J. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention—an Intervention Trial Evaluating Rosuvastatin) trial. J. Am. Coll. Cardiol. 55, 1266–1273 (2010).

    Article  CAS  Google Scholar 

  6. Tonelli, M. et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110, 1557–1563 (2004).

    Article  CAS  Google Scholar 

  7. Wanner, C. et al. for the German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353, 238–248 (2005).

    Article  CAS  Google Scholar 

  8. Fellström, B. C. et al. for the AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 360, 1395–1407 (2009).

    Article  Google Scholar 

  9. Strippoli, G. F. & Craig, J. C. Sunset for statins after AURORA? N. Engl. J. Med. 360, 1455–1457 (2009).

    Article  CAS  Google Scholar 

  10. Strippoli, G. F. et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 336, 645–651 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Otago Christchurch, 2 Riccarton Avenue, Christchurch, 8140, New Zealand

    Suetonia C. Palmer

  2. Department of Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Via Nazionale 8/A, Santa Maria Imbaro, 66030, Italy

    Giovanni F. M. Strippoli

Authors
  1. Suetonia C. Palmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giovanni F. M. Strippoli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni F. M. Strippoli.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Palmer, S., Strippoli, G. Lipid-lowering in CKD—at the SHARP end of the evidence?. Nat Rev Nephrol 7, 609–611 (2011). https://doi.org/10.1038/nrneph.2011.136

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2011.136

  • Springer Nature Limited

Search

Navigation